bioAffinity Technologies, Inc.(BIAF),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BIAF bioAffinity Technologies, Inc.

Trading 12-23 13:39:44 EST

1.00

+0.01

+0.73%

High1.02	Low0.8800	Vol137.40K
Open1.01	D1 Closing0.9928	Amplitude14.09%
Mkt Cap15.58M	Tradable Cap8.71M	Total Shares15.58M
T/O127.74K	T/O Rate1.58%	Tradable Shares8.71M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"BIAF","market":"US","secType":"STK","nameCN":"bioAffinity Technologies, Inc.","latestPrice":1,"timestamp":1734979069500,"preClose":0.9928,"halted":0,"volume":137400,"delay":0,"floatShares":8708600,"shares":15584635,"eps":-0.784797,"marketStatus":"Trading","change":0.0072,"latestTime":"12-23 13:39:44 EST","open":1.009,"high":1.0199,"low":0.88,"amount":127740.028422,"amplitude":0.140915,"askPrice":1.01,"askSize":9,"bidPrice":0.98,"bidSize":100,"shortable":0,"etf":0,"ttmEps":-0.784797,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1734987600000},"marketStatusCode":2,"adr":0,"listingDate":1662004800000,"exchange":"NASDAQ","adjPreClose":0.9928,"preHourTrading":{"tag":"盘前","latestPrice":1.08,"preClose":0.9928,"latestTime":"08:19 EST","volume":400,"amount":424,"timestamp":1734959980373},"postHourTrading":{"tag":"盘后","latestPrice":1.01,"preClose":0.9928,"latestTime":"18:37 EST","volume":2697,"amount":2640.7298,"timestamp":1734737873340},"volumeRatio":0.658701},"requestUrl":"/m/hq/s/BIAF/tweets","defaultTab":"tweets","newsList":[{"id":"2493523462","title":"bioAffinity Technologies Boosts Sales with CyPath Lung","url":"https://stock-news.laohu8.com/highlight/detail?id=2493523462","media":"TipRanks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493523462?lang=en_us&edition=fundamental","pubTime":"2024-12-21 19:33","pubTimestamp":1734780791,"startTime":"0","endTime":"0","summary":"Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks. bioAffinity Technologies, Inc. reports a successful year in 2024, significantly boosting sales and operations through its lung cancer detection product, CyPath Lung. The company plans to expand its market presence in 2025, leveraging its growth in the U.S. healthcare system and focusing on key regions and markets, including the VA and military sectors, to further increase the accessibility and adoption of its test.bioAffinity Technologies, Inc. operates in the medical diagnostics industry, focusing on the early detection of lung cancer through its noninvasive test, CyPath Lung. The company aims to address the critical need for early cancer detection, holding patents in the U.S., the European Union, and Asia, with a significant market presence in these regions.See more data about BIAF stock on TipRanks’ Stock Analysis page.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/mZDcjNmmKhClNQkla1p5GA--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/d622151edd421d0d1465b02718e80caa","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/mZDcjNmmKhClNQkla1p5GA--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/d622151edd421d0d1465b02718e80caa"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/bioaffinity-technologies-boosts-sales-cypath-113311538.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bioaffinity-technologies-boosts-sales-cypath-113311538.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BIAF","BIAFW"],"gpt_icon":0},{"id":"2492397954","title":"Join bioAffinity Technologies’ Exclusive Live Investor Webinar and Q&A Session on Thursday, December 19","url":"https://stock-news.laohu8.com/highlight/detail?id=2492397954","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492397954?lang=en_us&edition=fundamental","pubTime":"2024-12-17 21:00","pubTimestamp":1734440400,"startTime":"0","endTime":"0","summary":"SAN ANTONIO, December 17, 2024----bioAffinity Technologies, Inc. , a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, invites investors to a webinar on Dec. 19, 2024, at 4:15 p.m. ET.The exclusive event, hosted by RedChip Companies, will feature bioAffinity President and CEO Maria Zannes who will share insight into how the Company addresses the urgent need for noninvasive, accurate early-stage cancer diagnosis through its first product, CyPath Lung. CyPath Lung improves early-stage detection of lung cancer, leading to increased survival, fewer unnecessary invasive procedures, reduced patient anxiety, and lower medical costs. In October 2024, bioAffinity secured a U.S. Federal Supply Schedule contract for CyPath Lung, making the test available to U.S. veterans and federal health service patients, which is expected to accelerate sales growth in the quarters ahead.Questions can be pre-submitted to BIAF@redchip.com or online during th","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/j710YZwBD126h.eti4vI5g--~B/aD0yMDE7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/54c51bbe493920a5f3c2c534d2757609","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/j710YZwBD126h.eti4vI5g--~B/aD0yMDE7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/54c51bbe493920a5f3c2c534d2757609"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/join-bioaffinity-technologies-exclusive-live-130000707.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BIAF","BIAFW"],"gpt_icon":0},{"id":"2490832853","title":"bioAffinity Technologies Set for Continued Expansion in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2490832853","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490832853?lang=en_us&edition=fundamental","pubTime":"2024-12-12 21:00","pubTimestamp":1734008400,"startTime":"0","endTime":"0","summary":"Noninvasive CyPath Lung test for lung cancer contributes to growing revenues. SAN ANTONIO, December 12, 2024----bioAffinity Technologies, Inc. , a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today reported that the successful execution of its pilot marketing program and steady growth in sales of the CyPath Lung test for early detection of lung cancers have set the stage for expansion and record revenues in 2025.CyPath Lung revenues are expected to continue growing in 2025 with expanded sales into strategic national markets and inclusion in the U.S. Federal Supply Schedule. This key procurement system provides streamlined access to state-of-the-art healthcare solutions for the Veterans Health Administration  and the Military Health System. CyPath Lung fills an important need for a noninvasive test to improve the early detection of lung cancer in patients at high risk. CyPath Lung can be used alone or in combination with other ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/LgPbAeb52.uVA4plvBVH3w--~B/aD0yMDE7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/859151e05b86579a3631c65506d97ddc","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/LgPbAeb52.uVA4plvBVH3w--~B/aD0yMDE7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/859151e05b86579a3631c65506d97ddc"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bioaffinity-technologies-set-continued-expansion-130000123.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BIAF","BIAFW"],"gpt_icon":0},{"id":"2489454980","title":"Veterans’ Research Foundation Spotlights CyPath® Lung’s Addition to the Federal Supply Schedule","url":"https://stock-news.laohu8.com/highlight/detail?id=2489454980","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489454980?lang=en_us&edition=fundamental","pubTime":"2024-12-05 21:00","pubTimestamp":1733403600,"startTime":"0","endTime":"0","summary":"SAN ANTONIO, December 05, 2024----bioAffinity Technologies, Inc. , a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, will join Federal Supply System  officials today in a joint presentation highlighting the Veterans Health Administration  award adding CyPath Lung to the FSS procurement system for the VA’s 1,380 healthcare facilities at a meeting of the National Association of Veterans’ Research and Education Foundations .The VHA, part of the U.S. Department of Veterans Affairs , serves 9.1 million veterans each year and is the largest integrated healthcare system in the country. CyPath Lung is available to healthcare providers through the FSS that is utilized by the VHA and the Military Health System to streamline access to state-of-the-art healthcare products and services.Veterans are at higher risk for lung cancer due to older age, smoking and environmental exposure during and after military service. Through programs like the L","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/1lM7WqOF6VWZqWIdP9rYVA--~B/aD0yMDE7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/2f827e06a9421c9cb4154939361dad7f","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/1lM7WqOF6VWZqWIdP9rYVA--~B/aD0yMDE7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/2f827e06a9421c9cb4154939361dad7f"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/veterans-research-foundation-spotlights-cypath-130000143.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["US7Y.BOND","BK4149","US12M.BOND","US30Y.BOND","US5Y.BOND","US6M.BOND","BIAFW","US2Y.BOND","BIAF","US10Y.BOND","US3Y.BOND","FSS"],"gpt_icon":0},{"id":"2483487073","title":"bioAffinity Technologies Reports $2.4M Revenue For Q3 2024; Expanded CyPath Lung Test Sales To Physicians In Illinois, Alabama, And Louisiana; Now Receiving Orders From Physicians In 11 States","url":"https://stock-news.laohu8.com/highlight/detail?id=2483487073","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483487073?lang=en_us&edition=fundamental","pubTime":"2024-11-14 21:20","pubTimestamp":1731590437,"startTime":"0","endTime":"0","summary":"Expanded CyPath® Lung test sales to physicians in Illinois, Alabama, and Louisiana; now receiving orders from physicians in 11 statesNumber of physician offices signed increased 75% over Q2 2024Reaffirmed $9.6","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41971030/bioaffinity-technologies-reports-2-4m-revenue-for-q3-2024-expanded-cypath-lung-test-sales-to-physic","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"bioAffinity Technologies Reports $2.4M Revenue For Q3 2024; Expanded CyPath Lung Test Sales To Physicians In Illinois, Alabama, And Louisiana; Now Receiving Orders From Physicians In 11 States","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIAF"],"gpt_icon":0},{"id":"2483877805","title":"bioAffinity Technologies Reports $2.4 Million Revenue for Q3 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2483877805","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483877805?lang=en_us&edition=fundamental","pubTime":"2024-11-14 21:00","pubTimestamp":1731589205,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241114:nTUA623Y9J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BIAFW","BK4139","BIAF"],"gpt_icon":0},{"id":"2483877209","title":"bioAffinity Technologies Inc Qtrly EPS $-0.16","url":"https://stock-news.laohu8.com/highlight/detail?id=2483877209","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483877209?lang=en_us&edition=fundamental","pubTime":"2024-11-14 21:00","pubTimestamp":1731589205,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241114:nTUA623Y9J:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BIAF"],"gpt_icon":0},{"id":"2483087743","title":"Press Release: bioAffinity Technologies Reports $2.4 Million Revenue for Q3 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2483087743","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483087743?lang=en_us&edition=fundamental","pubTime":"2024-11-14 21:00","pubTimestamp":1731589200,"startTime":"0","endTime":"0","summary":"Expanded CyPath Lung test sales to physicians in Illinois, Alabama, and Louisiana; now receiving orders from physicians in 11 states. Number of physician offices signed increased 75% over Q2 2024. Reaffirmed $9.6 million 2024 revenue forecast for wholly owned Precision Pathology subsidiary. bioAffinity Technologies, Inc. , a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases, today reported financial results for the three months ended September 30, 2024.Generated quarterly revenue of $2.4 million in the third quarter of. More than 1,300% growth rate for CyPath Lung orders in first nine. Number of physician offices signed increased by 75% compared to the. second quarter of 2024, setting the stage for acceleration of CyPath. Lung through 1,380 government health care facilities. Approximately 8,000. Referrals and word-of-mouth from physicians, including key opinion. in states beyond Texas; now rece","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIAF"],"gpt_icon":0},{"id":"2480199589","title":"BRIEF-BioAffinity Technologies Appoints New Chief Science Officer To Spearhead Product Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2480199589","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480199589?lang=en_us&edition=fundamental","pubTime":"2024-11-04 22:32","pubTimestamp":1730730776,"startTime":"0","endTime":"0","summary":"Nov 4 (Reuters) - bioAffinity Technologies Inc   :   * BIOAFFINITY TECHNOLOGIES APPOINTS NEW CHIEF SCIENCE OFFICER TO SPEARHEAD PRODUCT DEVELOPMENTSource text:    Further company coverage:    (Reuters.Briefs@thomsonreuters.com)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BIAF"],"gpt_icon":0},{"id":"2480004300","title":"BioAffinity Technologies appoints William Bauta, Ph.D. Chief Science Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2480004300","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480004300?lang=en_us&edition=fundamental","pubTime":"2024-11-04 21:15","pubTimestamp":1730726150,"startTime":"0","endTime":"0","summary":"bioAffinity Technologies (BIAF) announced that William Bauta, Ph.D., has been appointed Chief Science Officer. Before joining bioAffinity in 2016 a...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bioaffinity-technologies-appoints-william-bauta-ph-d-chief-science-officer?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bioaffinity-technologies-appoints-william-bauta-ph-d-chief-science-officer?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BIAF","BK4139"],"gpt_icon":0},{"id":"2480307080","title":"bioAffinity Technologies Appoints New Chief Science Officer to Spearhead Product Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2480307080","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480307080?lang=en_us&edition=fundamental","pubTime":"2024-11-04 21:00","pubTimestamp":1730725204,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241104:nTUA6KCG94:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BIAF","BK4139","BIAFW"],"gpt_icon":0},{"id":"2480588187","title":"bioAffinity Technologies Appoints New Chief Science Officer to Spearhead Product Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2480588187","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480588187?lang=en_us&edition=fundamental","pubTime":"2024-11-04 21:00","pubTimestamp":1730725200,"startTime":"0","endTime":"0","summary":"Dr. William Bauta, bioAffinity Senior Vice President of Research and Development and former Associate Director of Science at Genzyme and Ilex, steps into new role with the retirement of Dr. Vivienne Rebel. Dr. Bauta is responsible for multiple Company inventions and patents supporting bioAffinity’s diagnostic and therapeutic advancements, including improvements to optimize CyPath Lung, the Company’s noninvasive test to detect early-stage lung cancer, that both improved performance and cut costs. His discoveries have expanded the Company’s patent portfolio and added to a growing list of publications. In addition to bioAffinity patents on which he is a named inventor, he holds multiple healthcare-related patents and has published in more than a dozen scientific journals, including the journal Science.CyPath Lung uses proprietary advanced flow cytometry and artificial intellig","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/ItQNjwTTpvwFz.E3ehvRPQ--~B/aD0yMDE7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/a8127d65ac48654886d55d2de9741a0a","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/ItQNjwTTpvwFz.E3ehvRPQ--~B/aD0yMDE7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/a8127d65ac48654886d55d2de9741a0a"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bioaffinity-technologies-appoints-chief-science-130000876.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BIAF","BIAFW","BK4139"],"gpt_icon":0},{"id":"2479995782","title":"bioAffinity Technologies Secures Japanese Patent for Lung Cancer Diagnostic Method","url":"https://stock-news.laohu8.com/highlight/detail?id=2479995782","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479995782?lang=en_us&edition=fundamental","pubTime":"2024-10-30 22:42","pubTimestamp":1730299352,"startTime":"0","endTime":"0","summary":"bioAffinity Technologies  said Wednesday it received a Japanese patent for its CyPath Lung diagnostic test method, which predicts lung cancer risk.The patent expands bioAffinity's portfolio to 17 granted patents, the company said.Shares of bioAffinity rose 2.7% in recent trading.Price: 1.34, Change: +0.03, Percent Change: +2.69","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BIAF","BK4139"],"gpt_icon":0},{"id":"2479920604","title":"bioAffinity Technologies Announces Award of Japanese Patent for CyPath® Lung","url":"https://stock-news.laohu8.com/highlight/detail?id=2479920604","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479920604?lang=en_us&edition=fundamental","pubTime":"2024-10-30 20:00","pubTimestamp":1730289600,"startTime":"0","endTime":"0","summary":"SAN ANTONIO, October 30, 2024----bioAffinity Technologies, Inc. , a biotechnology company focused on the need for noninvasive tests for the detection of early-stage lung cancer and other lung diseases, today announced that the Japan Patent Office has issued a Certificate of Grant of Patent to bioAffinity Technologies for the method of predicting the likelihood of lung cancer used by the CyPath Lung diagnostic test for early-stage lung cancer.bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company’s first product, CyPath Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath Lung is marketed as a Laboratory Developed Test  by Precision Pathology Laboratory","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/RFrWoB6BVo4KfZVjkxVDJw--~B/aD0yMDE7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/08136d77632d30ff54df7c3e7d867cb9","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/RFrWoB6BVo4KfZVjkxVDJw--~B/aD0yMDE7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/08136d77632d30ff54df7c3e7d867cb9"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bioaffinity-technologies-announces-award-japanese-120000732.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BIAF","BIAFW"],"gpt_icon":0},{"id":"2477889227","title":"BioAffinity Technologies announces closing of $2.6M registered direct offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2477889227","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477889227?lang=en_us&edition=fundamental","pubTime":"2024-10-22 02:22","pubTimestamp":1729534964,"startTime":"0","endTime":"0","summary":"BioAffinity Technologies (BIAF) announced it has closed its previously announced registered direct offering with institutional investors for the pu...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bioaffinity-technologies-announces-closing-of-2-6m-registered-direct-offering?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bioaffinity-technologies-announces-closing-of-2-6m-registered-direct-offering?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BIAF"],"gpt_icon":0},{"id":"2477867015","title":"Wallachbeth Capital Announces Closing of bioAffinity Technologies $2.6 Million Registered Direct Offering & Concurrent Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2477867015","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477867015?lang=en_us&edition=fundamental","pubTime":"2024-10-21 23:39","pubTimestamp":1729525141,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241021:nTUA4KMW72:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BIAF"],"gpt_icon":0},{"id":"2477860246","title":"WallachBeth Capital Announces Closing of bioAffinity Technologies $2.6 Million Registered Direct Offering & Concurrent Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2477860246","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477860246?lang=en_us&edition=fundamental","pubTime":"2024-10-21 23:39","pubTimestamp":1729525140,"startTime":"0","endTime":"0","summary":"JERSEY CITY, N.J., Oct. 21, 2024 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc.,a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, has closed its previously announced registered direct offering with institutional investors for the purchase and sale of 2,048,294 shares  of common stock at a price of $1.30 per share and concurrent private placement of common warrants  to purchase up to 2,662,782 shares of common stock at an exercise price of $1.50 per common share for gross proceeds of $2,662,782 before deducting placement agent fees and other offering expenses payable by the Company. The Warrants are initially exercisable on the date that the Company's stockholders approve the exercise of the Warrants and the issuance of the shares upon exercise thereof and will expire five years from the date of such approval.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/7OV4tyxQqPwRvFvbutrDEA--~B/aD0xODg7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/08d6b078574aa4a530f8d5620e223fd7","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/7OV4tyxQqPwRvFvbutrDEA--~B/aD0xODg7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/08d6b078574aa4a530f8d5620e223fd7"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/wallachbeth-capital-announces-closing-bioaffinity-153900722.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/wallachbeth-capital-announces-closing-bioaffinity-153900722.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BIAF","BK4139","BIAFW"],"gpt_icon":0},{"id":"2477861069","title":"bioAffinity Technologies Announces Closing of $2.6 Million Registered Direct Offering & Concurrent Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2477861069","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477861069?lang=en_us&edition=fundamental","pubTime":"2024-10-21 22:45","pubTimestamp":1729521900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241021:nTUA1VT1PT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BIAF","BK4139","BIAFW"],"gpt_icon":0},{"id":"2476292726","title":"Wallachbeth Capital Announces Pricing of bioAffinity Technologies $2.66 Million Registered Direct Offering & Concurrent Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2476292726","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476292726?lang=en_us&edition=fundamental","pubTime":"2024-10-19 02:57","pubTimestamp":1729277862,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241018:nTUAC96HQJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BIAF","BK4139"],"gpt_icon":0},{"id":"2476260223","title":"BioAffinity Technologies Down 25% on Stock Sale, Warrant Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2476260223","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476260223?lang=en_us&edition=fundamental","pubTime":"2024-10-19 01:16","pubTimestamp":1729271760,"startTime":"0","endTime":"0","summary":"BioAffinity Technologies shares declined after the company announced a $2.66 million registered direct offering of stock and a concurrent private placement of warrants.Shares were down 25%, to $1.59, Friday and are up about 8% this year.The maker of the CyPath lung cancer test said it agreed to sell 2.05 million shares for $1.30 each. The private placement includes 2.66 million warrants with an exercise price of $1.50 a share.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BIAF"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.bioaffinitytech.com;ir.bioaffinitytech.com","stockEarnings":[{"period":"1week","weight":0.0675},{"period":"1month","weight":-0.2183},{"period":"3month","weight":-0.5181},{"period":"6month","weight":-0.4359},{"period":"1year","weight":-0.32},{"period":"ytd","weight":-0.3249}],"compareEarnings":[{"period":"1week","weight":-0.0216},{"period":"1month","weight":0.0011},{"period":"3month","weight":0.0403},{"period":"6month","weight":0.0857},{"period":"1year","weight":0.2506},{"period":"ytd","weight":0.2437}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung. It offers CyPath lung, a diagnostic test, for early detection of lung cancer. The company was incorporated in 2014 and is based in San Antonio, Texas.","exchange":"NASDAQ","name":"bioAffinity Technologies, Inc.","nameEN":"bioAffinity Technologies, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"bioAffinity Technologies, Inc.(BIAF),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest bioAffinity Technologies, Inc.(BIAF) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"bioAffinity Technologies, Inc.,BIAF,bioAffinity Technologies, Inc.股票,bioAffinity Technologies, Inc.股票老虎,bioAffinity Technologies, Inc.股票老虎国际,bioAffinity Technologies, Inc.行情,bioAffinity Technologies, Inc.股票行情,bioAffinity Technologies, Inc.股价,bioAffinity Technologies, Inc.股市,bioAffinity Technologies, Inc.股票价格,bioAffinity Technologies, Inc.股票交易,bioAffinity Technologies, Inc.股票购买,bioAffinity Technologies, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"bioAffinity Technologies, Inc.(BIAF),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest bioAffinity Technologies, Inc.(BIAF) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction